Search AI Products and News

At the latest JP Morgan Healthcare Conference in 2025, NVIDIA and Innophore announced an exciting collaboration to launch an AI-driven drug safety screening platform named CavitOmiX by the end of January 2025. This platform aims to improve the efficiency and accuracy of drug design through the analysis of protein binding sites, marking a revolutionary transformation in the field of drug development. Christian Gruber, CEO of Innophore.

AI drug development company Genesis Therapeutics recently announced that it has secured additional investment from Nvidia's venture capital arm, NVentures, though the specific amount remains undisclosed. This move marks a further deepening of the collaboration between the two parties, aimed at accelerating the development of Genesis's AI platform GEMS (Genesis Exploration of Molecular Space), which focuses on utilizing physics-based AI for structure-driven drug design.

NVIDIA recently announced that its open-source BioNeMo™ biomolecular AI framework has gained widespread adoption in the pharmaceutical field, attracting significant attention from pharmaceutical companies, biotech innovators, and AI researchers. The introduction of this framework marks the formal entry of AI-assisted drug development into the supercomputing era. As a specialized AI toolkit for biomolecular research, the BioNeMo framework offers revolutionary breakthroughs for the pharmaceutical industry. Researchers can leverage this framework to significantly enhance the computational scale of AI models, analyze massive datasets more efficiently, and achieve remarkable advancements.

Biotech startup Chai Discovery has launched the AI model Chai-1, aimed at predicting molecular structures to aid drug development. This model surpasses Google's DeepMind AlphaFold in accuracy and has been supported by OpenAI and Thrive Capital. Chai-1's free web interface and open-source code encourage non-commercial research. The model excels in predicting various types of molecules, particularly demonstrating unexpected accuracy when data is incomplete, contributing significantly to drug development.

Biotechnology company Chai Discovery has received nearly $30 million in investment from Thrive Capital and OpenAI within six months of its founding. The company focuses on the application of biotechnology in drug development, developing innovative technologies that can predict biochemical molecular structures and reprogram molecular interactions, aiming to transform biology into 'engineering.' Chai Discovery's goal is to accelerate and optimize the drug development process by enhancing drug molecule design through technologies such as artificial intelligence and machine learning.

Israeli artificial intelligence startup CytoReason recently announced the completion of an $80 million funding round, with investors including industry giants such as Nvidia, Pfizer, OurCrowd, and Thermo Fisher Scientific. The company plans to use the funds to accelerate the development of its AI platform for disease modeling and drug discovery.Founded in 2016 and headquartered in Tel Aviv, CytoReason's AI platform extracts insights from human disease data to create computational disease models

Recently, scientists published a study on protein-ligand complex structure prediction in the journal 'Nature Machine Intelligence'. The new method, NeuralPLexer, predicts structures using deep generative models with only the protein sequence and ligand molecule graph as input. NeuralPLexer leverages a multiscale deep learning system to enhance prediction success rates and is expected to play a significant role in drug discovery. This research provides insights for exploring the field of protein-ligand complex structure prediction.

Indian startup Ceremorphic has launched a life sciences division to accelerate drug development using its AI chip technology platform. The Ceremorphic life sciences division employs a new technology platform called BioCompDiscoverX. The company's goal is to identify better candidate molecules from the outset and bring new drugs to market faster and at a lower cost.

The Tsinghua-based startup Shuimu Molecular has released ChatDD (Drug Design), a next-generation drug development assistant. ChatDD covers all stages of drug project initiation, preclinical research, and clinical trials, improving the efficiency of drug development. The team also launched ChatDD-FM 100B, the world's first multimodal biomedical dialogue model with 100 billion parameters. ChatDD-FM 100B has excelled in four specialized tasks in the medical field, being the only model with an average score exceeding 90. This innovation is expected to accelerate

AI pharma company Generate has raised $273 million in funding. The company will use the funds to support drug development in various disease areas, including cancer, infectious diseases, and immunological disorders. Generate utilizes AI to replace trial-and-error methods in drug discovery and to create new protein-based therapies.

California-based startup Genesis Therapeutics has successfully raised $200 million in funding. This round was co-led by Andreessen Horowitz and an undisclosed life sciences investor. Genesis plans to use the funds to advance its AI drug projects in clinical trials and expand its research into new areas.